Gefticip Tablet
Marketer
Cipla Ltd
Salt Composition
Gefitinib (250mg)
Overview Gefticip Tablet
Erlotinib tablets treat advanced non-small cell lung cancer. This medication is prescribed for patients with metastatic disease, abnormal epidermal growth factor receptor (EGFR) genes, and no prior cancer treatment. Dosage should strictly follow your physician's instructions; continue taking the medication for the prescribed duration, which is determined by your individual response and needs. Regular liver function monitoring may be recommended. Common side effects include nausea, diarrhea, dry skin, and decreased appetite. Increased fluid intake can help mitigate side effects. Report any concerning or worsening side effects to your doctor immediately. Seek immediate medical attention if you experience oral ulceration, visual changes, or respiratory distress. Women should utilize effective contraception throughout treatment and for one month post-treatment to prevent pregnancy. Always inform your doctor of all other medications you are currently taking.
Uses of Gefticip Tablet
Lung cancer (excluding small cell type)
Major Benefits of Gefticip Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Swallow the Gefticip Tablet whole; avoid chewing, crushing, or breaking it. While you can take it with or without food, consistent timing is recommended.
Common Side effects of Gefticip Tablet:
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Vomiting
- Weakness
- Weight loss
- Eating disorder
- Allergic reaction
How to use Gefticip Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. The tablet should be swallowed whole; avoid chewing, crushing, or breaking it. Gefticip Tablet can be administered with or without food, however, consistent timing is recommended.
How Gefticip Tablet works:
Gefticip tablets are a cancer treatment that inhibits the activity of a mutated protein responsible for cancerous cell proliferation, thus hindering or slowing tumor growth.
SAFETY ADVICE
AlcoholUNSAFE
Combining Gefticip Tablet and alcohol is strongly discouraged due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Using Gefticip Tablet during pregnancy is considered unsafe due to confirmed risks to the fetus. Nevertheless, a physician might exceptionally prescribe it in life-threatening emergencies where potential benefits outweigh the hazards. Seek medical advice before use.
Breast feedingCONSULT YOUR DOCTOR
The use of Gefticip Tablets while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Driving ability may be impaired by the side effects of Gefticip Tablet.
KidneyCAUTION
Patients with significant kidney impairment should use Gefticip Tablet cautiously, as dose modification may be necessary. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Using Gefticip Tablet in patients with liver disease appears to pose minimal risk. Available evidence indicates dose modification may be unnecessary, but physician consultation is advised.
What if you forget to take Gefticip Tablet :
Omit any missed Gefticip Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Gefticip Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline amines |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
3,018 People bought this recently